Targets › IGF1R
14 programs from 12 companies in 27 trials: 13 Phase 3, 6 Phase 2, 4 Phase 1, 4 Phase 4; Ophthalmology, Oncology, Cardiovascular; next expected readout Nov 2026.
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. (UniProt, P08069)
Open in Phaseline: the race on IGF1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) | Teprotumumab (N01) Insulin-like growth factor I receptor antagonist | IGF1R | Phase 4 | Thyroid Eye Disease | Jun 2028 |
| Amgen | Teprotumumab Insulin-like growth factor I receptor antagonist | IGF1R | Phase 3 | Thyroid Eye Disease | Nov 2026 |
| Viridian Therapeutics | VRDN-003 Humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF- | IGF1R | Phase 3 | Thyroid Eye Disease (TED); Thyroid Eye Disease | Nov 2026 |
| Minghui Pharmaceutical (Hangzhou) | MHB018A Humanized anti-IGF1R antibody | IGF1R | Phase 3 | Thyroid Associated Ophthalmopathies; Thyroid Eye Disease (TED); Thyroid Eye Disease, TED | Dec 2026 |
| Innovent Biologics (Suzhou) | IBI311 IGF-1 receptor antagonist | IGF1R | Phase 3 | Thyroid Eye Disease; Thyroid Associated Ophthalmopathies | Dec 2026 |
| Zai Lab (Shanghai) | ZL-1109 (VRDN-003) IGF-1 receptor antagonist | IGF1R | Phase 3 | Thyroid Eye Disease (TED) | Mar 2027 |
| National Cancer Institute (NCI) | Ganitumab Insulin-like growth factor I receptor antagonist | IGF1R | Phase 3 | Metastatic Ewing Sarcoma | Sep 2027 |
| Sling Therapeutics | linsitinib Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor | IGF1R, INSR | Phase 3 | Thyroid Eye Disease, TED; Thyroid Eye Disease | Jun 2028 |
| University of Washington | pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (WOKVAC) Plasmid DNA vaccine encoding tumor-associated antigens (IGFBP2, HER2, IGF1R) to stimulate | IGFBP2, HER2, IGF1R | Phase 2 | Anatomic Stage I Breast Cancer AJCC v8 | Dec 2026 |
| National Cancer Institute (NCI) | Cixutumumab Insulin-like growth factor I receptor antagonist | IGF1R | Phase 2 | Metastatic Esophageal Adenocarcinoma | Mar 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | WOKVAC pUMVC3-based vaccine targeting IGFBP2, HER2, and IGF1R | IGFBP2, ERBB2, IGF1R | Phase 2 | Breast Cancer Female | Dec 2027 |
| OHB Neonatology | Mecasermin Rinfabate (OHB-607) Insulin-like growth factor I receptor agonist | IGF1R | Phase 2 | Bronchopulmonary Dysplasia | Jan 2028 |
| QuantumLeap Healthcare Collaborative | Ganitumab Insulin-like growth factor I receptor antagonist | IGF1R | Phase 2 | Breast Neoplasms | Dec 2030 |
| Candid Therapeutics | Cizutamig (CND106) IGF-1 receptor antagonist | IGF1R | Phase 1 | Generalized Myasthenia Gravis; Systemic Lupus Erythematosus (SLE); Thyroid Eye Disease, TED; Rheumatoid Arthritis (RA) | Dec 2027 |
Thyroid Eye Disease (6) Thyroid Eye Disease, TED (4) Thyroid Eye Disease (TED) (4) Thyroid Associated Ophthalmopathies (4) Bronchopulmonary Dysplasia (1) Generalized Myasthenia Gravis (1) Systemic Lupus Erythematosus (SLE) (1) Rheumatoid Arthritis (RA) (1) Metastatic Ewing Sarcoma (1) Breast Neoplasms (1) Anatomic Stage I Breast Cancer AJCC v8 (1) Breast Cancer Female (1)
small molecule (5), mixed (5), antibody (2), protein or peptide (1), other (1)
Innovent Biologics (Suzhou) (2) National Cancer Institute (NCI) (2) OHB Neonatology (1) Amgen (1) Candid Therapeutics (1) Viridian Therapeutics (1) Minghui Pharmaceutical (Hangzhou) (1) Sling Therapeutics (1) QuantumLeap Healthcare Collaborative (1) Zai Lab (Shanghai) (1) University of Washington (1) H. Lee Moffitt Cancer Center and Research Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.